Evaluation of risk for symptomatic vertebral fracture using Cox proportional hazard regression (HR) model.
| Variables | HR (95% CI) | p |
|---|---|---|
| Initial age (every 10 yrs) | 1.83 (1.51–2.23) | < 0.0001 |
| BMI (every 1 BMI) | 0.99 (0.93–1.05) | 0.686 |
| Smoking | 1.18 (0.71–1.98) | 0.525 |
| Alcohol use | 1.40 (0.730–2.67) | 0.315 |
| Menstruation | 0.93 (0.51–1.68) | 0.800 |
| Initial dose of PSL (every 10 mg/day) | 1.44 (1.22–1.69) | < 0.001 |
| GC pulse therapy | 1.36 (0.79–2.35) | 0.265 |
| No. GC dose increases | 2.52 (2.04–3.12) | < 0.001 |
| Cumulative dose of PSL (every 1 g) | 0.92 (0.91–0.94) | < 0.001 |
| SLE | 2.02 (1.08–3.76) | < 0.05 |
| RA | 1.67 (0.82–3.38) | 0.158 |
| SS | 1.15 (0.55–2.38) | 0.715 |
| SSc/MCTD | 2.47 (1.27–4.80) | < 0.01 |
| PM/DM | 1.28 (0.63–2.60) | 0.496 |
| Microscopic polyangiitis | 2.87 (1.30–6.32) | < 0.01 |
BMI: body mass index; PSL: prednisolone; GC: glucocorticoid; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; SS: Sjögren’s syndrome; SSc: systemic sclerosis; MCTD: mixed connective tissue disease; PM/DM: polymyositis/dermatomyositis.